User:SDZeroBot/NPP sorting/STEM/Chemistry: Difference between revisions

Revision as of 13:51, 8 August 2025

Revision as of 01:46, 31 August 2025

(44 intermediate revisions by the same user not shown)

Line 1:

{{User:SDZeroBot/NPP sorting/header|count=1220|date=831 August 2025|ts=1301:5146, 831 August 2025 (UTC)}}

{| class="wikitable sortable"

Line 10:

! scope="col" style="width: 4em;" | Notes

|-

| 2024-1101-1015

| [[Qing-YunGadolinium(III) Chenselenate]] <small>(ChineseChemical chemist (1929-2023)compound)</small>

| Gadolinium(III) selenate is an inorganic compound with the [[chemical formula]] Gd₂(SeO₄)₃. It exists as the anhydrate and octahydrate. The octahydrate transforms into the anhydrate when heated to 130&nbsp;°C.

| Qing-Yun Chen ({{zh|s=陈庆云|p=Chén Qìngyún}}; 25 January 1929 – 2 March 2023) was a Chinese [[organic chemist]] and member of the [[Chinese Academy of Sciences]], specializing in the field of organic fluorine chemistry.

| Stub

| data-sort-value=556622447 | [[Special:Contribs/Noxoug1Praseodymium-141|Noxoug1Praseodymium-141]] (556622447)

|

|-

| 2024-01-11

| [[Samarium(III) antimonide]] <small>(Chemical compound)</small>

| Samarium antimonide is a binary inorganic compound of [[samarium]] and [[antimony]] with the formula SmSb. It forms crystals.

| Stub

| data-sort-value=22447 | [[Special:Contribs/Praseodymium-141|Praseodymium-141]] (22447)

| C

|-

| 2024-01-18

| [[Porous polymer]]

| Porous polymers are a class of [[porous media]] materials in which [[monomer]]s form [[2D polymer|2D]] and [[3D polymers]] containing angstrom- to nanometer-scale pores formed by the arrangement of the monomers. They may be either crystalline or amorphous. Subclasses include [[covalent organic framework]]s (COFs), [[hydrogen-bonded organic framework]]s (HOFs), [[metal-organic framework]]s (MOFs), and [[porous organic polymer]]s (POPs).

| Start

| data-sort-value=82888895 | [[Special:Contribs/Tokisaki KurumiMichael7604|Tokisaki KurumiMichael7604]] (82888895)

|

|-

| 2024-1201-1722

| [[DazadrolPraseodymium monoselenide]] <small>(Dazadrol is anChemical antidepressantcompound)</small>

| Praseodymium monoselenide is a compound with the chemical formula PrSe. It forms crystals.

| Dazadrol is a synthetic [[antidepressant]] developed by [[Schering-Plough|Schering Corp]] in the late 1960s. It acts primarily as a [[noradrenaline reuptake inhibitor]], increasing concentrations of noradrenaline in the [[synaptic cleft]], which is believed to underlie its antidepressant effects.

| Stub

| data-sort-value=26022447 | [[Special:Contribs/Mo18ekulaPraseodymium-141|Mo18ekulaPraseodymium-141]] (26022447)

|

|-

| 20252024-0501-1926

| [[TransitionIron(III) metal catalytic asymmetric dearomatization reactionsselenite]] <small>(Category of organic chemicalChemical reactionscompound)</small>

| Iron(III) selenite is an inorganic compound with the chemical formula Fe₂(SeO₃)₃. It exists anhydrous form and as various hydrates. The heptahydrate is produced by the reaction of [[ferric chloride]] and [[selenous acid]] (or [[sodium selenite]]) at a pH of 1.05.

| Catalyzed asymmetric dearomatization reactions (CADA reactions) are a category of asymmetric [[Dearomatization reaction|dearomatization reactions]] that catalytically transform [[Aromatic compound|aromatic compounds]] into enantioenriched [[Polycyclic compound|polycycles]] and [[Heterocyclic compound|heterocyclic]] skeletons. The term was coined in 2012 by You et al.

| Start

| data-sort-value="A0"|FA

| data-sort-value=3822447 | [[Special:Contribs/PchemExtraordinairePraseodymium-141|PchemExtraordinairePraseodymium-141]] (3822447)

|

|-

| 20252024-0511-2310

| [[Cefepime/sulbactamQing-Yun Chen]] <small>(CombinationChinese antibioticchemist consisting of the IV generation(1929-2023))</small>

| Qing-Yun Chen ({{zh|s=陈庆云|p=Chén Qìngyún}}; 25 January 1929 – 2 March 2023) was a Chinese [[organic chemist]] and member of the [[Chinese Academy of Sciences]], specializing in the field of organic fluorine chemistry.

| Cefepime/sulbactam is a 1:1 [[fixed-dose combination]] of [[cefepime]] (a fourth-generation cephalosporin) and [[sulbactam]] (a β-lactamase inhibitor). The combination exerts a bactericidal effect by disrupting bacterial cell wall synthesis through transpeptidase inhibition, thereby impairing peptidoglycan cross-linking.

| CStart

| data-sort-value=378392 | [[Special:Contribs/ХокусTokisaki Покус 333Kurumi|Хокус ПокусTokisaki 333Kurumi]] (378392)

|

|-

| 20252024-0501-3110

| [[Fudosteine]] <small>(Chemical compound)</small>

| [[Musahaqah]]

| Fudosteine (Cleanal) is a [[mucolytic agent]]. In Japan, it is approved for the treatment of [[bronchial asthma]], [[chronic bronchitis]], [[pulmonary emphysema]], [[bronchiectasis]], [[pulmonary tuberculosis]], [[pneumoconiosis]], atypical [[mycobacterial disease]], and [[diffuse panbronchiolitis]].

| Musaheqeh ({{Langx|ar|مساحقه}}) is a legal and religious term. In [[Fiqh|Islamic jurisprudence]] ([[fiqh]]) and under the [[Islamic Penal Code of Iran]], musaheqeh refers to a situation in which an adult, mentally competent, and consenting [[woman]] brings her [[Sex organ|genitalia]] into contact with the genitalia of another woman.

| Stub

| data-sort-value=24435014 | [[Special:Contribs/JesusisGreat7Innerstream|JesusisGreat7Innerstream]] (24435014)

|

|-

Line 50 ⟶ 64:

| Stub

| data-sort-value=646 | [[Special:Contribs/BaeyerDrewson|BaeyerDrewson]] (646)

|

|-

| 2025-05-22

| [[225Ac-PSMA-R2]] <small>(Investigational radiopharmaceutical)</small>

| 225Ac-PSMA-R2 is an investigational [[radiopharmaceutical]] developed by [[Novartis]] for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) and [[metastatic castration-resistant prostate cancer]] (mCRPC). It is a [[targeted alpha therapy]] (TAT) combining [[actinium-225]] (225Ac), an alpha-emitting [[radionuclide]], with PSMA-R2, a small-molecule [[ligand]] targeting [[prostate-specific membrane antigen]] (PSMA), a protein overexpressed in prostate cancer cells.

| C

| data-sort-value=5566 | [[Special:Contribs/Noxoug1|Noxoug1]] (5566)

|

|-

Line 63 ⟶ 70:

| ¹⁷⁷Lu-NNS309 is an investigational radiopharmaceutical compound currently under development by Novartis Pharmaceuticals for the treatment of various [[Neoplasm|solid tumors]]. The compound is being evaluated in Phase I clinical trials for patients with pancreatic, lung, breast, and colorectal cancers.

| C

| data-sort-value=55665704 | [[Special:Contribs/Noxoug1|Noxoug1]] (55665704)

|

|-

| 20222025-0107-0629

| [[NitazenesOpRegen]] <small>(ClassAllogeneic ofcell drugstherapy)</small>

| OpRegen (also known as RG6501) is an investigational allogeneic cell therapy developed by Lineage Cell Therapeutics for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The therapy consists of human retinal pigment epithelial (RPE) cells administered via subretinal injection as a single treatment.

| Nitazenes are a chemically defined class of substances derived from the [[Parent structure|parent compound]] [[nitazene]]. Nitazenes were developed in the second half of the 1950s by the Swiss [[Novartis|Ciba AG]] as [[analgesic|pain-relieving agents]]. They are important as [[central nervous system|centrally]] active, selective [[μ-opioid receptor]] [[agonist]]s.

| C

| data-sort-value=381115704 | [[Special:Contribs/Idoghor MelodyNoxoug1|Idoghor MelodyNoxoug1]] (381115704)

|

|-

| 2025-07-1531

| [[Vatinoxan]] <small>(Pharmaceutical compound)</small>

| [[2025 Los Angeles County Sheriff's Department training facility explosion]]

| Vatinoxan, originally known as MK-467, is an [[Alpha-2_adrenergic_receptor#Antagonists|α₂-adrenergic receptor antagonist]] used in veterinary medicine alongside [[Alpha-2_adrenergic_receptor#Agonists|α₂-adrenergic receptor agonists]] to counteract [[vasoconstriction]] and [[hypertension]] while maintaining sedation. Vatinoxan does not cross the [[blood–brain barrier]] giving it a unique pharmacological profile compared to the other α₂-adrenergic receptor antagonists and distinct clinical application.

| On July 18, 2025, an explosion occurred at the [[Los Angeles County Sheriff's Department]] (LASD) Biscailuz Center training facility in [[East Los Angeles, California]].&nbsp;The explosion killed three police officers and is the deadliest incident for the LASD since 1857.

| StartC

| data-sort-value=177499 | [[Special:Contribs/DesertIVSacristy|DesertIVSacristy]] (177499)

|

| [[Wikipedia:Articles for deletion/2025 Los Angeles County Sheriff's Department training facility explosion|Past AfD]]

|-

| 2025-0701-2919

| [[OpRegenFluorescence upconversion]] <small>(AllogeneicUltrafast laser cellspectroscopic therapytechnique)</small>

| Fluorescence upconversion (FU) is an [[Ultrafast laser spectroscopy|ultrafast laser spectroscopic]] technique. It is a variant of [[sum-frequency generation]] (of which the [[second-harmonic generation]] (SHG) is a special case) but applied to the detection of the incoherent [[fluorescence]]. It is therefore closely related to the [[Optical Kerr Gating]] (OKG) technique.

| OpRegen (also known as RG6501) is an investigational allogeneic cell therapy developed by Lineage Cell Therapeutics for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The therapy consists of human retinal pigment epithelial (RPE) cells administered via subretinal injection as a single treatment.

| C

| data-sort-value=5566104 | [[Special:Contribs/Noxoug1Ozzwah|Noxoug1Ozzwah]] (5566104)

|

|-

| 2025-06-16

| [[Sefaxersen]] <small>(Antisense oligonucleotide therapy under development)</small>

| Sefaxersen (also known as RO7434656, RG6299, ISIS-696844 and IONIS-FB-LRx) is an investigational [[antisense oligonucleotide]] (ASO) drug developed by [[Roche Holding AG]] in partnership with [[Ionis Pharmaceuticals]]. It targets [[complement factor B]] (CFB) to treat [[complement system]]-mediated diseases, primarily [[IgA nephropathy]] (IgAN) and [[geographic atrophy]] (GA) secondary to [[age-related macular degeneration]].

| C

| data-sort-value=5704 | [[Special:Contribs/Noxoug1|Noxoug1]] (5704)

|

|-

| 2025-08-18

| [[Jens Bruun de Neergaard]] <small>(Danish judge and landowner)</small>

| Jens Bruun de Neergaard (14 June 1742 – 22 April 1788) was a [[Denmark|Danish]] judge and landowner. He owned [[Svenstrup (manor house)|Svenstrup Manor]], at [[Borup, Køge|Broup]], [[Køge Municipality]], whouse present main building he constructed in the 1780s. On 31 May 1780, alongside his younger brother, Johan Thomas de Neergaard (1745–1806), he was ennobled by [[letters patent]].

| Start

| data-sort-value=88166 | [[Special:Contribs/Ramblersen2|Ramblersen2]] (88166)

|

|-

| 2025-08-04

| [[CinnabarinicHellenic acidChampionship (Tennis)]] <small>(ChemicalTennis compoundtournament)</small>

| The Hellenic Championship is an [[ATP 250 tournaments|ATP 250 tournament]] held in [[Athens]], [[Greece]]. The event is played on indoor [[hardcourt]] at the [[OAKA Basketball Arena]], a multi-purpose venue that was used for the [[2004 Summer Olympics]]. It replaces the [[Belgrade Open]] on the calendar and it is scheduled to debut in November 2025.

| Cinnabarinic acid is a [[metabolite]] formed through the oxidative processing of [[tryptophan]]. It is an endogenous metabolite of the [[kynurenine pathway]] of [[tryptophan]] catabolism, formed by oxidative dimerization of two molecules of [[3-hydroxyanthranilic acid]]. It functions both as a partial agonist at type 4 [[metabotropic glutamate receptors]] (mGlu₄) and as a ligand for the [[aryl hydrocarbon receptor]] (AhR), with implications for [[neuroprotection]] and [[immunomodulation]].

| Stub

| data-sort-value=4021 | [[Special:Contribs/Haddad Maia fan|Haddad Maia fan]] (4021)

|

|-

| 2025-08-13

| [[Structural Dynamics Response Assay]] <small>(Biochemical analysis procedure)</small>

| The structural dynamics response (SDR) assay is a type of [[biophysical]] test used to measure [[ligand binding]] to a target [[protein]]. The assay is configured as a simple mix and read format that can be conducted in very low volumes, therefore suitable for [[drug discovery]] applications such as [[high throughput screening]] (HTS), or in the development of a drug candidate during [[medicinal chemistry]] optimization cycles.

| Start

| data-sort-value=374 | [[Special:Contribs/Hoffmacs|Hoffmacs]] (374)

|

|-

| 2025-08-27

| [[Ferrugine]] <small>(Chemical compound)</small>

| Ferrugine is a [[tropane alkaloid]] discovered in the basic [[extract]] of the Australian rainforest tree ''[[Darlingia ferruginea]]'' where it occurs in the leaves and stems. The structure has been [[Chemical_structure#Structural_elucidation|determined]] through [[spectroscopic analysis]] and confirmed by [[chemical synthesis]].

| Stub

| data-sort-value=0 | [[Special:Contribs/2.101.56.53|2.101.56.53]]

|

|-

| 2025-0508-22

| [[Zimei Bu]] <small>(researcher)</small>

| Zimei Bu, PhD is a protein chemist in the [[City College of New York]], where she is Professor of Chemistry and Biochemistry and Laboratory Director.

| Stub

| data-sort-value=24 | [[Special:Contribs/Wang Walton|Wang Walton]] (24)

|

|-

| 2025-05-04

| [[Erythrocyte-based drug delivery]] <small>(Drug delivery method)</small>

| Erythrocyte-based drug delivery systems (EBDDS) use [[red blood cells]], their membranes, or their components to release and deliver pharmaceutical agents throughout the body in a controlled manner. Because red blood cells circulate for long periods of time and are potentially non-[[immunogenic]], they are an attractive vector for [[drug delivery]] via the circulatory system.

| C

| data-sort-value=6 | [[Special:Contribs/DrugDelivery2025|DrugDelivery2025]] (6)

|

|-

| 2004-07-29

| [[Figure of Insensitivity]]

| Figure of Insensitivity (''F of I'') is an inverse scale of measure of the impact [[shock sensitivity|sensitivity]] of an [[explosive]] substance. In this particular context the term 'Insensitivity' refers to the likelihood of initiation/[[detonation]] by impact, [[friction]], [[electrostatic discharge]], application of [[flame]], etc.

| Start

| data-sort-value=370 | [[Special:Contribs/FlarpenX20.133.0.11|FlarpenX20.133.0.11]] (37)

|

|}

<span style="font-style: italic; font-size: 85%;">Last updated by [[User:SDZeroBot|SDZeroBot]] ^{''[[User:SD0001|operator]] / [[User talk:SD0001|talk]]''} at 1301:5146, 831 August 2025 (UTC)</span>